Cancer stem cells lie at the root of chronic myelogenous leukemia (CML) and mediate its continued growth. Their resistance to current therapies results in an inability to eradicate the disease. In this issue of Cancer Cell, Li et al. identify SIRT1 as a new target for eliminating CML cancer stem cells
Cancer stem cells play a critical role in disease initiation and insensitivity to chemotherapy in nu...
Leukemia stem cells (LSCs) are likely to be the source for both therapeutic resistance and relapse i...
Studies on chronic myeloid leukemia (CML) have served as a paradigm for cancer research and therapy....
SIRT1 inhibition facilitates elimination of CML stem cells by Imatinib, in part via p53 activation. ...
Chronic myeloid leukemia (CML) arises as a consequence of a chromosomal translocation giving rise to...
The eradication of tumours by targeting malignant stem cell populations, or cancer stem cells (CSCs)...
Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder that arises in the hemato...
SummaryBCR-ABL tyrosine kinase inhibitors (TKI) fail to eliminate quiescent leukemia stem cells (LSC...
Chronic myeloid leukemia stem cells (CML LSCs) are a rare and quiescent population that are resistan...
Chronic myeloid leukemia (CML) is a clonal stem cell disorder that is characterized by the acquired ...
BCR-ABL tyrosine kinase inhibitors (TKI) fail to eliminate quiescent leukemia stem cells (LSC) in ch...
Despite decades of clinical trials, the prognosis of patients with acute myeloid leukemia (AML) rema...
SIRT1 inhibition facilitates elimination of CML stem cells by Imatinib, in part via p53 activation. ...
Chronic myeloid leukemia (CML) is sustained by a rare population of primitive, quiescent, BCR-ABL<...
peer reviewedIn tumours, a significant fraction of neoplastic cells are engaged in the cell cycle (g...
Cancer stem cells play a critical role in disease initiation and insensitivity to chemotherapy in nu...
Leukemia stem cells (LSCs) are likely to be the source for both therapeutic resistance and relapse i...
Studies on chronic myeloid leukemia (CML) have served as a paradigm for cancer research and therapy....
SIRT1 inhibition facilitates elimination of CML stem cells by Imatinib, in part via p53 activation. ...
Chronic myeloid leukemia (CML) arises as a consequence of a chromosomal translocation giving rise to...
The eradication of tumours by targeting malignant stem cell populations, or cancer stem cells (CSCs)...
Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder that arises in the hemato...
SummaryBCR-ABL tyrosine kinase inhibitors (TKI) fail to eliminate quiescent leukemia stem cells (LSC...
Chronic myeloid leukemia stem cells (CML LSCs) are a rare and quiescent population that are resistan...
Chronic myeloid leukemia (CML) is a clonal stem cell disorder that is characterized by the acquired ...
BCR-ABL tyrosine kinase inhibitors (TKI) fail to eliminate quiescent leukemia stem cells (LSC) in ch...
Despite decades of clinical trials, the prognosis of patients with acute myeloid leukemia (AML) rema...
SIRT1 inhibition facilitates elimination of CML stem cells by Imatinib, in part via p53 activation. ...
Chronic myeloid leukemia (CML) is sustained by a rare population of primitive, quiescent, BCR-ABL<...
peer reviewedIn tumours, a significant fraction of neoplastic cells are engaged in the cell cycle (g...
Cancer stem cells play a critical role in disease initiation and insensitivity to chemotherapy in nu...
Leukemia stem cells (LSCs) are likely to be the source for both therapeutic resistance and relapse i...
Studies on chronic myeloid leukemia (CML) have served as a paradigm for cancer research and therapy....
DOI
Add to ORKG